TrumpRx ’s promised drug-price cuts expose a deeper systemic flaw, positioning direct-to-patient clinical pathways as the infrastructure pharma must build to turn political headlines into real access and outcomes.
Pouria Sanae
Advertisement
Co-founder and CEO, ixlayer
Articles by Pouria Sanae
Physicians remain central even as DTP programs are implemented.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
2
Pharmaceutical Executive Daily: FDA Approves Wegovy HD
3
FDA Approves Wegovy HD Injectable Under Accelerated Approval
4
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
5